Clinical Trials Logo

Clinical Trial Summary

Constitutional mutations of genes involved in telomere repair and maintenance are responsible for "telomeropathy" (" Congenital Dyskeratosis "). Attrition of telomeres promotes cell senescence and genetic instability. The penetrance and severity of organ damage (pulmonary, hematological, liver, and neurological) is variable, depending on the gene involved, the generation concerned (anticipation phenomenon) and also environmental factors.

In cases of bone marrow failure, the only curative treatment is hematopoietic stem cell transplant, often limited by pulmonary and / or hepatic involvement or the absence of a suitable HLA match donor. The pulmonary phenotype is most often that of idiopathic pulmonary fibrosis. In severe forms, a lung transplant is proposed in the absence of contraindications. Anti-fibrotic treatments are not very effective or not evaluated. The observed decrease in the vital capacity of these patients is 300 ml / year, abnormally high compared to idiopathic forms. Evolution without transplant is in both situations rapidly unfavorable; the prognosis after lung or marrow transplant is also worse than that of similar transplants without telomeres disease.

Danazol has been used for over 4 decades in acquired and constitutional bone marrow failure in the absence of a therapeutic alternative. In telomeropathy, retrospective data on small cohorts indicate a haematological response rate of 60-70%. A prospective study in the United States recently showed a haematological response at 1 year in 78% of cases (10 of 12 evaluable patients) with stabilization of vital capacity. Retrospective data (unpublished) on patients treated in France have shown more side effects and more frequent treatment interruptions and eventually weaker haematological response rate. This study aim to evaluate the benefit of danazol at 12 months on the clinical response.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03710356
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Flore SICRE DE FONTBRUNE, MD PhD
Phone 142494949
Email flore.sicre-de-fontbrune@aphp.fr
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date October 20, 2018
Completion date October 20, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04638517 - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Phase 2
Completed NCT02844478 - Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging N/A
Completed NCT04763525 - Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals. N/A
Active, not recruiting NCT02299245 - Rosuvastatin Effect on Telomere-telomerase System in ACS Phase 4
Recruiting NCT05508321 - Nasal Brushing for the Diagnosis and Understanding of Telomeropathies N/A
Completed NCT03982589 - Telomere Length in Relation to Acute Stress Response in Critical Care Patients
Not yet recruiting NCT06430073 - Effect of Infections and Global DNA Methylation on Frailty Trajectories in Hospitalized Older Patients (INFRAGEN)
Not yet recruiting NCT05978921 - Physical Exercise in Patients With Schizophrenia N/A
Terminated NCT05715372 - Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy N/A
Active, not recruiting NCT03286699 - Lifestyle Change for Better Health N/A
Not yet recruiting NCT05598359 - TA-65 and Aging Associated Microvascular Dysfunction N/A
Recruiting NCT06056375 - Biological and Behavioral Outcomes of Community Nature Walks Phase 1
Completed NCT02055456 - Nandrolone Decanoate in the Treatment of Telomeropathies Phase 1/Phase 2
Recruiting NCT04211714 - Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure Phase 1
Completed NCT03459053 - CBART: The Reduction of Psychological and Physiological Stress in Women Undergoing IVF N/A